scholarly journals Clonotypic analysis of T cell reconstitution after haematopoietic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency

2007 ◽  
Vol 148 (3) ◽  
pp. 450-460 ◽  
Author(s):  
H. Okamoto ◽  
C. Arii ◽  
F. Shibata ◽  
T. Toma ◽  
T. Wada ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Severe Combined Immunodeficiency ◽  
Haematopoietic Stem Cell ◽  
Combined Immunodeficiency ◽  
T Cell Reconstitution

Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency

Blood ◽  
2006 ◽  
Vol 108 (2) ◽  
pp. 763-769 ◽  
Author(s):  
José A. Borghans ◽  
Robbert G. Bredius ◽  
Mette D. Hazenberg ◽  
Helene Roelofs ◽  
Els C. Jol-van der Zijde ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Severe Combined Immunodeficiency ◽  
Combined Immunodeficiency ◽  
Hematopoietic Stem ◽  
T Cell Reconstitution

The immune system of patients with severe combined immunodeficiency (SCID) reconstitutes to a large extent during the first years after hematopoietic stem cell transplantation (HSCT). It was suggested, however, that accelerated loss of thymus output may cause impaired immune function at the long term. To address this issue, we studied patients with SCID who underwent allogeneic HSCT 5 to 32 years earlier and identified early determinants of long-term T-cell reconstitution. A variety of immune parameters were analyzed both early (1-4 years) and late (5-32 years) after HSCT. Late after HSCT, a clear distinction could be made between a group of 8 patients with impaired T-cell reconstitution and 11 patients with good immune reconstitution. Importantly, in patients with decreased long-term T-cell reconstitution, T-cell recovery was already poor early after HSCT, demonstrating that long-term immune failure was not caused by accelerated loss of thymus output or long-term graft failure, but resulted from poor early grafting. The number of T-cell receptor excision circles (TRECs) early after HSCT was most predictive for long-term T-cell reconstitution. Frequent monitoring of T-cell immunity and TREC numbers early after HSCT may thus serve to timely identify patients who will fail to reconstitute properly and who may need additional treatment.

scholarly journals Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma

2003 ◽  
Vol 120 (2) ◽  
pp. 304-309 ◽  
Author(s):  
Masahiro Kami ◽  
Tamae Hamaki ◽  
Shigesaburo Miyakoshi ◽  
Naoko Murashige ◽  
Yoshinobu Kanda ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Cell Leukaemia

scholarly journals Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3125
Author(s):  
Chathuri Abeyakoon ◽  
Carrie van der Weyden ◽  
Sean Harrop ◽  
Amit Khot ◽  
Michael Dickinson ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Haematopoietic Stem Cell ◽  
Phase Ii Studies

Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.

Sign in / Sign up

Export Citation Format

Share Document